Pacific Edge's revenue climbs, US future still uncertain

Pacific Edge's revenue climbs, US future still uncertain
Very strong revenue growth, but profit still some distance away (Image: Pacific Edge)
Ella Somers
A boom in Pacific Edge’s Cxbladder test sales boosted the firm’s operating revenue soar by 71%, with a helping hand from favourable exchange rates.Chief executive Peter Meintjes said the 2023 financial year had been a year of “enormous change and achievement” for the cancer diagnostic company.“Pacific Edge is geared for growth,” he told the NZX.Operating revenue for the twelve months to March 31 rose $19.6 million, up from $11.4m in the previous year while total revenue jumped 88% to $26.1m.The revenue climb...

More Markets

NZ sharemarket up 0.1% on flat trading day
Markets Market close

NZ sharemarket up 0.1% on flat trading day

The S&P/NZX 50 Index closed at 11,790.92, up 14.18 points or 0.12%.

Advent International eyes NZ deals with Aussie outpost
Markets

Advent International eyes NZ deals with Aussie outpost

US private equity giant says NZ key market for growth.

These shares are 'priced for awful'
Markets

These shares are 'priced for awful'

Kathmandu, SkyCity and Fletcher shares are under pressure. Some are taking the plunge.